2 Psychedelic Bellwethers That Are Gearing Up To Go Public In 2021Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use DisorderMindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial ExperiencePure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction PlatformPsyched Wellness’ Mycological Research Continues To Take Serious Strides ForwardMindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsPure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction PlatformMYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned ListingTryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory BoardCYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramNuminus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic ProductsPsyched Wellness Commences Antioxidant and Anti-Inflammatory Study on MuscimolMindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical TrialsEntheon Biomedical Announces Investment and Business Arrangement with Heading Health LLCPsyched Wellness Has Commenced Research on Muscimol for Various AilmentsAion Therapeutic Announces Closing of Non-Brokered Private PlacementPsyched Wellness Commences Pre-Clinical Trials of Amanita MuscariaHavn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an

Technical420 Site Search

Returned 25 result(s).

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Cybin Inc. (NEO:CYBN), a life sciences company focused on psychedelic therapeutics, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel to leverage its innovative technology, Kernel Flow, for its upcoming sponsored clinical work. Click here to view the accompanying film. Flow is a…

CYBIN Provides Update on Patent Filings & Development of Therapeutics Program

Cybin Inc. (NEO:CYBN) (“Cybin” or the “Company”), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to provide an update on its on its eight patent filings, which cover the Company’s novel therapeutics, delivery mechanisms and treatment regiments. Cybin’s updated corporate presentation will be available at www.cybin.com. The Company is…

Cybin Corp. Acquires Adelia Therapeutics To Bolster IP Portfolio and Human Capital

Yesterday morning, Cybin Inc. (NEO:CYBN) reported a major milestone announcing the closing of 100% of Adelia Therapeutics Inc. The transaction is transformational for Cybin’s drug development program and we are favorable on the potential that is associated with the combined company. A Transformational All-Stock Acquisition for Cybin One of the…

CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings

Cybin Inc. (NEO:CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has closed on its acquisition of 100% of the shares in Adelia Therapeutics Inc. for up to CDN$20,161,575 (approximately USD$15.75 million). Transaction Highlights Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access…

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth

 Cybin Inc. (NEO:CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CDN$20,161,575 (approximately USD$15.75 million) in an all-stock transaction. The Transaction is subject to the satisfaction or waiver of…

Cybin Corp. Will Make Its Debut Today On The NEO Under The Symbol “CYBN”

CYBIN CORP. is a public company focusing on advancing psychedelic pharmaceutical therapies, delivery mechanisms, novel compounds and protocols as potential therapies for various psychiatric and neurological conditions. The company represents a differentiated opportunity when compared to other operators. Cybin is also developing technologies and delivery systems that aim to improve…

Cybin Completes Reverse Take-Over Transaction

CYBIN Inc. (formerly Clarmin Explorations Inc.), a life sciences company initially focused on psychedelic pharmaceutical therapies, today announced it has completed its previously announced reverse takeover of Clarmin Explorations Inc. pursuant to the terms of an amalgamation agreement dated June 26, 2020, as amended on October 21, 2020, among Cybin…

The Psychedelic Sector Is Getting A Major Momentum Boost Post U.S. Election

The US election proved to be a catalyst for the psychedelic therapy industry after two major ballot initiatives were passed in the District of Columbia and in Oregon. According to the Associated Press, D.C. voters passed legislation that would make the possession and use of certain psychedelic plants the lowest…

Cybin Corp. Is Cashed Up and Primed For It’s Public Market Debut

2020 has been a banner year for the psychedelic therapy market, and the industry is not even in the first inning of an impressive growth cycle. One of the most important trends that we have identified with psychedelic therapy companies is the amount of capital raised by these businesses. So…

CYBIN and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTO

CLARMIN EXPLORATIONS INC. (TSXV: CX.V) and CYBIN CORP. (“ CYBIN ” or the “ Company ”), a life sciences company focused on psychedelic pharmaceutical therapies, announce the closing of a private placement offering by the Company (the “ Offering ) of an aggregate of 60,000,000 subscription receipts (the “ Subscription Receipts ”) at a price of CDN$0.75 per…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link